What Healius Ltd does

Healius Ltd (ASX: HLS) is one of Australia's largest specialty diagnostic and pathology providers, operating a national network of 2,063 approved collection centres and 95 laboratories through a portfolio of regional brands — Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS) — alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trial bioanalysis (Agilex Biolabs), and veterinary pathology (Vetnostics). The company processes approximately one in three pathology samples taken in Australia and employs 8,000+ people across the country.

The core technology stack is built around Laboratory Information Systems (LIS) that manage pathology data across the laboratory network, augmented by AI tools ('AI co-workers') used to support pathologists in result interpretation and clinical decision support, plus a national pharmacogenomics (PGx) testing capability within the Genomic Diagnostics brand. Distribution is centred on the owned collection-centre network, with patients referred by general practitioners and specialists who account for the bulk of pathology demand.

Revenue is generated primarily through Medicare Australia bulk-billing rebates for routine pathology services (a stream subject to multi-decade stagnation in rebate indexation), supplemented by direct commercial pathology contracts with employers and government clients — including an approximately A$60 million, five-year Australian Defence Force contract — plus revenue from specialized testing partnerships such as the BCAL Diagnostics Avantect cancer screening distribution agreement. 1H FY2026 revenue was A$688.1 million (+3.8% YoY), with underlying EBIT of A$7.9 million, A$18 million in annualized cost savings, a net loss of A$30.4 million, and genomics segment revenue growing 21.6% over the period.

Name

Healius Ltd

Legal name

Healius Ltd

Website

https://healius.com.au

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Healius Ltd is one of Australia's largest pathology providers, operating 2,000+ collection centres and 95 laboratories under regional brands and processing roughly one in three pathology samples nationally for patients, GPs, and government clients.

Ownership category

akta.pro rank

Product category

Pathology Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Pathology services
• Diagnostic testing
• Laboratory services
• Medical diagnostics
• Genetic testing

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Medicare Pathology Rebates: Bulk-billed pathology services funded through Medicare Australia rebates. The company faces chronic underfunding of Medicare pathology rebates spanning approximately 24 years without inflation indexation.
2. Commercial Pathology Services: Direct pathology testing services to commercial clients including employers, government departments, and corporate customers
3. Government Contracts: Contracts with government entities including Australian Defence Force worth approximately $60 million over 5 years
4. Specialized Testing Partnerships: Revenue from distributing specialized tests through partnership arrangements with companies like BCAL Diagnostics
5. Veterinary Pathology Services: Vetnostics brand provides veterinary pathology laboratory services through Specialist Veterinary Services Pty Ltd

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Healius operates a national pathology and diagnostic services network providing specialty diagnostic testing to consumers and referring practitioners across Australia. Core offerings include clinical pathology (blood tests, tissue diagnostics), genetic and pharmacogenomic testing, dermatopathology, functional gastroenterology testing, veterinary pathology, and bioanalytical services for clinical trials, delivered through 2,000+ collection centres and 95 laboratories under multiple regional brands. Revenue is generated primarily through Medicare bulk-billed rebates, commercial contracts with employers and government entities, and distribution partnerships for specialised third-party tests.

Product overview

Healius Ltd operates as a multi-brand pathology laboratory network providing specialty diagnostic services across Australia. The portfolio consists of a unified pathology network (Healius Pathology Network) with 12 regional sub-brands covering all Australian states and territories. The main brands include Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS), alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trials (Agilex Biolabs), and veterinary pathology (Vetnostics). The network operates from 95 laboratories and over 2,000 collection centres, processing approximately one in three pathology samples in Australia.

Differentiator

Problem solved

Functional benefit

Brands

• Agilex Biolabs: Bioanalysis and sample analysis services with 25 years of experience in performing regulated bio analysis.
• Genomic Diagnostics

Products and services

• Healius Pathology Network
• Laverty Pathology
• Dorevitch Pathology
• QML Pathology
• Abbott Pathology
• Western Diagnostic Pathology (WDP)
• TML Pathology
• Genomic Diagnostics
• Agilex Biolabs
• IQ Pathology
• Kossard Dermatopathologists
• Gastrolab
• Vetnostics
• Avantect Early Detection Blood Tests (BCAL partnership distribution)

Quantifiable outcome

• 70% of medical decisions involve pathology
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• BCAL DiagnosticscoreStrategic or Co-development Partner · 26 March 2026BCAL Diagnostics is expanding commercial rollout of its Avantect early detection blood tests for pancreatic and ovarian cancers through a new partnership with Healius, making tests available through pathology collection centres across Australia. Tests are priced at $1,495 per test or $1,995 for combined testing.
• RACGP (Royal Australian College of General Practitioners)coreStrategic or Co-development Partner · 17 March 2026Healius Pathology Network announced a strategic partnership with RACGP to enhance GP learning and professional development in pathology testing and interpretation.
• C2N DiagnosticsminorStrategic or Co-development Partner · 30 August 2022Healius announced partnership in precision medicine for timely detection of Alzheimer's disease with C2N Diagnostics.
• Minderoo FoundationminorStrategic or Co-development Partner · 11 May 2020Healius announced collaboration with Minderoo Foundation for COVID-19 testing during the pandemic.
• Global Diagnostics Network (GDN)minorStrategic or Co-development Partner · 11 October 2018Primary HealthCare (now Healius) joined Global Diagnostics Network as a Founding Member, providing access to global diagnostic expertise and network.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Australian Clinical Labs: Australian Clinical Labs is one of Australia's largest pathology providers and Healius' closest direct competitor. ACL attempted to acquire Healius for A$1.58bn in 2023 before the deal was blocked by the ACCC, highlighting their directly competitive positioning.
• Melbourne Pathology: Melbourne Pathology is a major Victorian pathology provider offering comprehensive diagnostic services. It directly competes with Healius' Dorevitch Pathology in the Victorian market.
• Healthscope Pathology: Healthscope operates hospital and pathology services across Australia, including Healthscope Pathology. It competes directly with Healius in providing pathology services to hospitals, GPs, and specialists nationwide.
• Douglass Hanly Moir Pathology: Douglass Hanly Moir is a subsidiary of Sonic Healthcare operating in NSW, providing pathology services through laboratories and collection centres. It competes directly with Healius' Laverty Pathology in overlapping geographies.
• Sonic Healthcare: Sonic Healthcare is the largest pathology/diagnostics provider in Australia and globally, operating laboratories and collection centres across multiple countries. It is Healius' primary direct competitor in Australian pathology with overlapping service offerings and customer segments.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies globally. It serves as a broad incumbent comparable to Healius in diagnostic testing services, advanced genomics, and employer health services.
• SYNLAB Group: SYNLAB is Europe's leading medical diagnostic services provider offering clinical laboratory testing across multiple countries. Comparable to Healius in core pathology services and specialized diagnostics including genomics.
• LabCorp: LabCorp is a leading global clinical laboratory services company. While primarily US-based, it represents the global benchmark for clinical laboratory business models and is comparable in service offerings to Healius' pathology operations.

Emerging players

• 4Cyte Pathology: 4Cyte Pathology is an Australian pathology provider offering diagnostic services through a network of collection centres and laboratories, competing with Healius for GP referrals and patient volume in selected markets.

Regional players

• Awanui Pathology: Awanui Pathology is a major New Zealand-based pathology laboratory network. It is comparable to Healius in business model and services but operates primarily across New Zealand rather than Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healius Ltd